Journal of Clinical Oncology
Articles in this Issue
Impact of pathologic necrosis on clinical outcomes following neoadjuvant radiation for soft tissue sarcoma.
e23565 Background: Tumor necrosis is a common pathologic finding in soft tissue sarcomas (STS) following neoadjuvant thera...
Anti–PD-1 immunotherapy with chemotherapy for poorly chemo-responsive thyroid and salivary gland tumors: The iPRIME study.
6124 Background: Clinical trial data guiding treatment of unresectable or metastatic salivary and thyroid gland cancers ar...
Does neoadjuvant chemotherapy reduce axillary lymph node dissection in postmenopausal ER+/HER2 <i>−</i> breast cancer?
e12634 Background: The role of neoadjuvant chemotherapy (NAC) in postmenopausal estrogen receptor–positive/human epidermal...
Low-dose tamoxifen for pre-cancer and early disease: A pooled analysis by menopausal status.
10515 Background: Adjuvant endocrine prevention reduces the risk of subsequent breast cancer events after ductal carcinoma...
TACE-HAIC combined with low-dose donafenib for unresectable hepatocellular carcinoma: A real-world study.
e16182 Background: The treatment of unresectable hepatocellular carcinoma (uHCC) remains challenging. Although the combina...
Evaluating quality of life outcomes in metastatic breast cancer: Effects of palliative home visits in northern Malaysia.
e13090 Background: Metastatic breast cancer (MBC) causes significant symptom burden and psychological distress especially...
A propensity score-matched analysis comparing first-line regional, systemic, and intralesional treatments for melanoma in-transit metastases in a contemporary patient population.
9524 Background: Unresectable melanoma in-transit metastases (ITM) can pose a significant clinical challenge. Our recently...
The role of combined T cell and NK cell activity in immune checkpoint inhibitor (ICI) therapy in endometrial cancer (EC).
5609 Background: The efficacy of ICI in EC has largely been attributed to high microsatellite instability (MSI-H) causing...
Baseline financial and credit status of participants enrolled in SWOG S1912CD.
11049 Background: Financial hardship is associated with adverse outcomes in cancer patients. While there is a critical nee...
Donafenib plus sintilimab combined with TACE or HAIC for unresectable hepatocellular carcinoma: A prospective single-arm phase II study.
e16179 Background: The combination of targeted therapy and immunotherapy has shown promising efficacy in patients (pts) wi...
Geospatial hotspot analysis of breast cancer in Ohio: Environmental and rural–urban disparities informing targeted prevention and treatment.
e22566 Background: Breast cancer is the most commonly diagnosed malignancy among women in the United States. In 2022, 10,6...
Large genomic rearrangements in germline <i>BRCA1/2</i> pathogenic variant architecture across tumor types.
e22636 Background: Germline BRCA1/2 pathogenic variation is structurally heterogen...
AI-based pre-screening of <i>BRCA1/2</i> mutation likelihood from routine H&E histopathology in unselected breast cancer cases using peakPredictBRCA.
546 Background: BRCA1/2 mutation status is essential for precision oncology in breast cancer, directly guiding therapy dec...
Comparative survival disparities and outcome in primary vs secondary central nervous system lymphoma (CNSL): A population-based analysis using Surveillance, Epidemiology, and End Results (SEER) program (2000-2022).
e14111 Background: Primary CNSL (PCNSL) is a rare, aggressive B-cell non-Hodgkin lymphoma limited to the CNS, while second...
Integrating multimodal data with artificial intelligence to predict postoperative recurrence in intrahepatic cholangiocarcinoma after curative resection.
e16294 Background: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy and carries a...
A randomized, phase II, double-blinded study of the efficacy of oleogel-S10 (AP101) gel for the treatment of grade 2/3 radiation dermatitis in breast cancer patients.
e24199 Background: Radiation therapy is a cornerstone of treatment for early-stage breast cancer; however, up to one third...
Pharmacovigilance signals of androgen receptor pathway inhibitors in non-geriatric men with prostate cancer: A FAERS disproportionality analysis.
e17045 Background: Age-restricted real-world safety patterns of androgen receptor pathway inhibitors (ARPIs) in prostate c...
Epigenetic ctDNA kinetics as a predictor of early progression in advanced E/GEJ cancers treated with CDK4/6 and VEGF inhibition therapy.
e16056 Background: Advanced esophageal and gastroesophageal junction (E/GEJ) tumors carry a poor prognosis and reliable ea...
De novo vs recurrent metastatic presentation and outcomes with first-line EGFR TKI in <i>EGFR</i> -mutant NSCLC.
e20766 Background: Approximately 20% of EGFR-mutant metastatic non-small cell lung cancer (NSCLC) presents as recurrent di...
A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA–positive colorectal cancer.
TPS3688 Background: Curative intent standard of care (SOC) management of colorectal cancer (CRC) involves surgical tumor r...
Access to immunotherapy and molecular diagnostics for lung adenocarcinoma in Syria: A mixed-methods study from the country’s main cancer center.
1557 Background: Immunotherapy is now a standard-of-care treatment for lung cancer across most stages. Access to immunothe...
Impact of prior malignancy on cardiac complications and mortality in patients with COVID-19.
12109 Background: Cancer accounts for approximately 600,000 deaths annually in the United States, and patients with cancer...
Effect of metformin on clinically significant chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
e24151 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity that negatively im...
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.
8506 Background: Pembrolizumab has been the standard first-line treatment for PD-L1 positive advanced NSCLC. Sac-TMT, a TR...
Trends in COPD-related mortality among adults with lung cancer in the United States, 1999-2025: A CDC WONDER analysis.
e20776 Background: Both COPD and lung cancer are major concerns worldwide. Lung cancer is an important comorbidity of COPD...